RESUMO
Left ventricular assist devices (LVADs) have marked a milestone in the evolution of treatment for patients with end-stage heart failure. Their popularity and use are steadily rising. This systematic review and meta-analysis aimed to evaluate the effectiveness of LVADs in improving the survival rate of patients with end-stage heart failure and to identify the complications or adverse events associated with LVAD use. Articles for this systematic review and meta-analysis were sourced from PubMed, Google Scholar, and the Cochrane Library databases. Only studies that met the predefined PICOS eligibility criteria were analyzed. LVADs significantly improved the 6, 12, 18, and 24-month survival rates in patients with end-stage heart failure compared to no LVAD or other therapies: OR 1.87 (95%CI [1.27-2.76]), OR 2.29 (95%CI [1.61-3.26]), OR 2.07 (95%CI [0.61-6.61]), and OR 1.73 (95%CI [0.88-3.41]) for 6, 12, 18, and 24 months, respectively. The incidence of adverse events was significantly higher in the LVAD group than in the non-LVAD treatments: bleeding OR 12.53 (95%CI [2.60-60.41]), infections OR 4.15 (95%CI [1.19-14.45]), stroke OR 2.58 (95%CI [1.38-4.82]), and arrhythmia OR 2.81 (95%CI [1.64-4.80]). Overall, complications were higher in the LVAD group compared to those without LVAD treatment. Hospital readmissions due to adverse events were significantly more frequent in the LVAD group, OR 2.98 (95%CI [1.38-6.43]). Despite the elevated risk of adverse events associated with LVADs, these devices have demonstrated a notable enhancement in the survival outcomes for patients with end-stage heart failure.
Assuntos
Insuficiência Cardíaca , Coração Auxiliar , Adulto , Humanos , Coração Auxiliar/efeitos adversos , Insuficiência Cardíaca/epidemiologia , Readmissão do Paciente , Taxa de Sobrevida , Resultado do TratamentoRESUMO
La artritis reumatoide se clasifica como una enfermedad articular autoinmune crónica poliarticular sistémica que afecta principalmente a manos y pies. El objetivo de este trabajo es mostrar información publicada que contribuye a direccionar el manejo de la artritis reumatoide con nuevos fármacos, a partir del conocimiento de aspectos novedosos relacionados con la fisiopatología y los avances recientes sobre un grupo importante de dianas para el tratamiento de esta enfermedad. Las modificaciones epigenéticas pueden regular la expresión génica sin alterar la secuencia del ADN. La regulación de los ARN no codificantes (ncRNA), la metilación del ADN, la metilación del ARN y las modificaciones de las histonas se consideran los principales mecanismos de las regulaciones epigenéticas. Numerosas investigaciones han establecido que varias anomalías en estos mecanismos terminan en el desarrollo de la AR. Este trabajo resume nuevas dianas, que incluyen proteínas, pequeños metabolitos moleculares y reguladores de la epigenética. Son dianas moleculares prometedoras para el descubrimiento de fármacos que alivien la aparición de enfermedades y resuelvan la falta de respuesta y las respuestas parciales, así como los efectos adversos de los FARME actuales. Es innegable que aún se necesitan mayores esfuerzos para definir con mayor precisión las vías de señalización subyacentes afectadas por estas moléculas recién descubiertas y para desarrollar métodos de terapia apropiados(AU)
Rheumatoid arthritis is classified as a systemic polyarticular chronic autoimmune joint disease that mainly affects the hands and feet. The objective of this work is to show published information that contributes to directing the management of RA with new drugs. Epigenetic modifications can regulate gene expression without altering the DNA sequence. Regulation of non-coding RNAs (ncRNAs), DNA methylation, RNA methylation, and histone modifications are considered the main mechanisms of epigenetic regulations. Numerous investigations have established that various abnormalities in these mechanisms lead to the development of RA. This work summarizes new targets, including proteins, small molecular metabolites and regulators of epigenetics. They are promising molecular targets for drug discovery to alleviate disease onset and resolve non-response and partial responses, as well as adverse effects of current DMARDs. It is undeniable that further efforts are still needed to further define the underlying signaling pathways affected by these newly discovered molecules and to develop appropriate therapy methods(AU)
Assuntos
Humanos , Masculino , Feminino , Artrite Reumatoide/história , Epigenômica/métodosRESUMO
La faringitis bacteriana es una enfermedad infectocontagiosa que históricamente ha afectado al ser humano durante cualquier etapa de su vida, resultando un área de estudió de importancia para la salud pública.Esta investigaciónpresenta el reporte epidemiológico de morbilidad de Faringitis Aguda Estreptocócica (FAE) atendidos en el dispensario del Seguro Social Campesino Llimpe Grande durante los meses de enero a julio del año 2019. Esto se logró, en dos fases apartir de la revisión de 2538 registros de morbilidad atendidos en el periodo de estudio, correlacionando los caracteres diagnósticos clínicos con la resolución de casos posterior a la indicación del tratamiento con terapia de antibióticos, información levantada a partir del 10% de historias clínicas, corroborando la misma con la población médica (n=9).La información fue analizada en Excel para la determinación de intervalos de confianza apoyado en estadística descriptiva.La FAE en el caso de Ecuador se asocia ala época húmeda, con prevalencia hacia el sexo femenino (Rm=0,2) para el periodo en estudio. Sintomatología:úvula inflamada enrojecida, petequias suaves, náuseas, dolor abdominal degarganta. Los casos se presentan en todas las edades con predominio en el grupo de 18 a 64 años. El 100% de los casos respondieron a la terapia de antibióticos solo un 1,14% no respondió a la antibioterapia por abandonar en forma tempranael mismo.Aún quedan preguntas por responder, por lo que hacemos un llamado a la comunidad científica en general a realizar acciones tendentes a optimizar los registros FAE, robusteciendo a futuro los reporte epidemiológico(AU)
Bacterial pharyngitis is an infectious disease that has historically affected humans during any stage of their life, resulting in an area of study of importance for public health. This research presents the epidemiological report of morbidity of Acute Streptococcal Pharyngitis (AED) treated at the Llimpe Grande Peasant Social Security dispensary during the months of January to July 2019. This was a chieved, in two phases, from there view of 2538 morbidity records attended in the study period, correlating the clinical diagnostic characteristics with there solution of cases after the indication of treat ment with antibiotic therapy, information gathered from the 10% of medical records, corroborating the same with the medical population (n = 9). The information was analyzed in Excel for the determination of confidence intervals supported by descriptive statistics. FAE in the case of Ecuador is associated with the wetseason, with a prevalence tow ards the female sex (Rm = 0.2) for the period understudy. Symptoms: red swollenuvula, mildpetechiae, nausea, abdominal sorethroat. Cases occur in all ages with a predominance in the 18 to 64 age group. 100% of the cases responded to antibiotictherapy, only 1.14% did not respond to antibiotic therapy dueto abandoning it early. There are still questions to be answered, so we call on the scientific community in general to take action saimed at optimizing AED records, streng the ning the epidemiological reports in the future(AU)